Emergency Deadline (June 1, 2026): FinCEN must enact laws that fully protect whistleblowers.
Submit Your Comment

Daniel Richardson
Pharmaceutical Whistleblower
Daniel Richardson reported his employer Bristol-Myers Squibb for illegal marketing drugs which resulted in increased Medicare and Medicaid costs. Richardson, and other whistleblowers, filed qui tam actions against the drug maker. In September of 2007, the Department of Justice announced a settlement in which Bristol-Myers Squibb agreed to pay $515 million to resolve the allegations.